Presentation is loading. Please wait.

Presentation is loading. Please wait.

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.

Published byYuliani Yanti Susman Modified over 6 years ago

Similar presentations

Presentation on theme: "F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke."— Presentation transcript:

1 F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke van den Berg, Johannes Oldenburg, Jan Astermark, Philip G. de Groot, Maurizio Margaglione, Arthur R. Thompson, Waander van Heerde, Jorien Boekhorst, Connie H. Miller, Saskia le Cessie, and Johanna G. van der Bom Blood Volume 119(12): March 22, 2012 ©2012 by American Society of Hematology

2 Flow diagram of study selection.
Flow diagram of study selection. Numbers of unique reports are indicated in parentheses. Samantha C. Gouw et al. Blood 2012;119: ©2012 by American Society of Hematology

3 Distribution of F8 genotypes.
Samantha C. Gouw et al. Blood 2012;119: ©2012 by American Society of Hematology

4 Pooled ORs of inhibitor development according to the F8 genotype
Pooled ORs of inhibitor development according to the F8 genotype. 2 indicates the between-study variance of lnOR. Pooled ORs of inhibitor development according to the F8 genotype.2 indicates the between-study variance of lnOR. Samantha C. Gouw et al. Blood 2012;119: ©2012 by American Society of Hematology

5 Pooled ORs of high-titer-inhibitor development according to the F8 genotype. 2 indicates the between-study variance of lnOR. Pooled ORs of high-titer-inhibitor development according to the F8 genotype.2 indicates the between-study variance of lnOR. Samantha C. Gouw et al. Blood 2012;119: ©2012 by American Society of Hematology

Download ppt "F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke."

Similar presentations

Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.

Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.
A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.
JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,
Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.

Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,
CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.

CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.
CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.
by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M

by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M
Do HSCs divide asymmetrically?

Do HSCs divide asymmetrically?
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
by Nadine Martel, James Lee, and Philip S. Wells

by Nadine Martel, James Lee, and Philip S. Wells
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use by Ida Martinelli, Anthonie W. A. Lensing, Saskia.

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use by Ida Martinelli, Anthonie W. A. Lensing, Saskia.
TCR-MHC-peptide(s): in vivo veritas

TCR-MHC-peptide(s): in vivo veritas
by Enli Liu, Melanie J. Percy, Christopher I

by Enli Liu, Melanie J. Percy, Christopher I
Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels by Carina J. M. van Schooten,

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels by Carina J. M. van Schooten,
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11):3909-3918 June 1, 1997 ©1997.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Similar presentations

Ads by Google